Anonymous . 1997 . Rapid diagnostic tests for tuberculosis . What is the appropriate use? Am J Respir Crit Care Med 155 : 1804–1814 .
Aronson N , Santosham M , Howard R , Comstock G , and Harrison, L. 1999 . The long-term efficacy of BCG vaccine . Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1999 . Washington, DC : .
Behr MA , Warren SA , Salamon H , Hopewell PC , Ponce de Leon A , Daley CL , and Small PM. 1999 . Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli . Lancet 353 : 444–449 .
Bond EC , Peck MG , and Scott, MB. 1998 . The future of philanthropic support for research . Scientist 13(21) : 15 .
Centers for Disease Control . 1989 . A strategic plan for the elimination of tuberculosis in the United States . MMWR 38 (S3) : 1–25 .
Centers for Disease Control and Prevention . 1992 . National action plan to combat multidrug-resistant tuberculosis in the United States . MMWR 41(RR11) : 1–48 .
Centers for Disease Control and Prevention . 1993 . Recommendations of the International Task Force for Disease Eradication . MMWR 42(RR16) : 1–25 .
Centers for Disease Control and Prevention . 1995 . Improving tuberculosis treatment and control: An agenda behavioral, social, and health services research . Proceedings for “Tuberculosis and Behavior, National Workshop on Research for the 21st Century, 1995.” Atlanta : Centers for Disease Control and Prevention .
Centers for Disease Control and Prevention . 1996 . The role of BCG vaccine in the prevention and control of tuberculosis in the United States . MMWR 45 (RR4) : 1–18 .
Centers for Disease Control and Prevention . 1998 . Population-Based Survey for Drug Resistance of Tuberculosis—Mexico, 1997 . MMWR 47 : 371–375 .
Centers for Disease Control and Prevention . 2000 . Targeted testing and treatment of latent tuberculosis infection . MMWR 49(RR-6) : 1–54 .
Colditz GA , Brewer TF , Berkey CS , et al. 1994 . Efficacy of BCG vaccine in the prevention of tuberculosis . Meta-analysis of the published literature . JAMA 271(9) : 698–702 .
Crawford JT. 1994 . New technologies in the diagnosis of tuberculosis . Semin Respir Infect 9 : 62(70 .
Cynamon MH , Klemens SP , Sharpe CA , and Chase S. 1999 . Activities of several novel oxazolidino nesagainst Mycobacterium tuberculosis in a murine model . Antimicrob Agents Chemother 43 : 1189(1190 .
Holden, M , Dubin MR , and Diamond PH. 1971 . Frequency of negative intermediate-strength tuberculin sensitivity in persons with active tuberculosis . N Engl J Med 285 : 1506–1509 .
Huebner RE , Schein MF , and Bass JB, Jr. 1993 . The tuberculin skin test . Clin Infect Dis 17 : 968–975 .
Iseman MD and Sbarbaro JA. 1991 . Short-course chemotherapy of tuberculosis . Hail Britannia (and friends!) . Am Rev Respir Dis 143(4) : 697–698 .
Lowrie DB , Tascon RE , Bonato VL , et al. 1999 . Therapy of tuberculosis in mice by DNA vaccination . Nature 400(6741) : 269–271 .
National Institutes of Health . 1998 . Blueprint for Vaccine Development . Report of a workshop held March 5–6, 1998, Rockville, MD.
NIAID . 2000 . Blueprint of tuberculosis vaccine development . Clinical Infectious Diseases Vol.30, Supp. 3 (June 2000) , 5233–5242 .
Nunn DR , and Douglas JE. 1980 . Anergy in active pulmonary tuberculosis: A comparison between positive and negative reactors and evaluation of 5 TU and 250 TU skin test doses . Chest 77 : 32–37 .